Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

Core Insights - ANI Pharmaceuticals, Inc. (ANIP) has reached a significant support level, indicating a potential investment opportunity from a technical perspective [1] - The recent breakout of ANIP's 50-day simple moving average above its 200-day moving average signifies a "golden cross," which is a bullish indicator [1] - Over the past four weeks, ANIP's stock has gained 10.9%, and it currently holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting a potential breakout [3] Technical Analysis - A golden cross consists of three stages: a downtrend that bottoms out, a shorter moving average crossing above a longer moving average, and continued upward momentum [2] - The golden cross is contrasted with a death cross, which indicates potential bearish price movement [2] Earnings Outlook - ANIP's positive earnings outlook for the current quarter strengthens the bullish case, with no earnings estimates decreasing in the past two months and three revisions higher [3] - The Zacks Consensus Estimate for ANIP has also increased, further supporting the positive sentiment around the stock [3][4]

Core Viewpoint - ANI Pharmaceuticals (ANIP) has shown a significant price increase of 10.9% over the past four weeks, with a mean price target of $81.50 indicating a potential upside of 26.8% from the current price of $64.26 [1] Price Target Analysis - The average price target consists of eight estimates ranging from a low of $62 to a high of $94, with a standard deviation of $9.13, indicating variability among analysts [2] - The lowest estimate suggests a decline of 3.5%, while the highest indicates a potential upside of 46.3% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about ANIP's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 23.9%, with three estimates moving higher and no negative revisions [10] - ANIP holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a useful guide for understanding price movement direction [12]

Core Viewpoint - ANI Pharmaceuticals, Inc. has launched Nitazoxanide Tablets, a generic version of Alinia®, highlighting its commitment to providing affordable, high-quality medicines [1][2]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics, with a mission of "Serving Patients, Improving Lives" [3]. - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [3]. Product Launch Details - The newly launched Nitazoxanide Tablets are 500 mg and represent a niche product with limited competition [1]. - U.S. annual sales for Nitazoxanide Tablets are approximately $36.1 million, based on December 2024 moving annual total (MAT) IQVIA data [2]. Partnership Information - ANI Pharmaceuticals has partnered with Biophore India Pharmaceuticals Pvt. Ltd. for the launch of Nitazoxanide Tablets, emphasizing a shared commitment to affordable medicines [2][4].

Core Points - ANI Pharmaceuticals, Inc. has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC for a one-time payment of $17.25 million, eliminating future royalty payments on net revenues of ILUVIEN and YUTIQ starting January 1, 2025 [1][2] - The buyout enhances ANI's financial flexibility and supports the growth of its Retina portfolio, aligning with the company's mission of "Serving Patients, Improving Lives" [2] Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology, rheumatology, nephrology, neurology, and pulmonology [2] - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [2]

Core Viewpoint - ANI Pharmaceuticals has received FDA approval for an expanded label for ILUVIEN, which now includes treatment for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to its existing indication for diabetic macular edema (DME) [1][4] Company Developments - The company plans to market ILUVIEN for chronic NIU-PS alongside DME in the U.S. later this year [4] - ANI has extended its supply agreement with Siegfried Holding AG for ILUVIEN through 2029, which includes upgrades to manufacturing equipment and significant capacity expansion [2] Product Indications - ILUVIEN is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and diabetic macular edema [3][5] Safety Information - ILUVIEN has contraindications for patients with active or suspected ocular infections, glaucoma with cup to disc ratios greater than 0.8, and known hypersensitivity to any components of the product [5] - Adverse reactions reported in clinical trials include cataracts (82% for DME), increased intraocular pressure (34% for DME), and various ocular and non-ocular reactions [6][7] Clinical Trial Data - In trials for DME, 34% of ILUVIEN patients experienced an increase in intraocular pressure of 10 mm Hg or more, compared to 10% of sham patients [6] - For chronic NIU-PS, ocular adverse reactions included cataract (56%), reduced visual acuity (15%), and macular edema (11%) [7][8] Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology [12]

Market Overview - The U.S. stock market experienced a downturn in early 2025 after a strong performance in 2023 and 2024, with the S&P 500 dropping 1.4% in February and continuing losses into March [1] - Investors are concerned about the economic effects of Trump's tariff policies, which may lead to inflation and hinder growth [1] - The Atlanta Fed forecasts a 2.8% contraction in the first quarter of 2025, raising recession concerns [1] Investment Strategy - In the current uncertain market, focusing on relative price strength is a beneficial strategy for investors, as stocks with strong fundamentals tend to perform better when market sentiment stabilizes [2] - Identifying stocks that have shown resilience during market turbulence can help investors position for potential upside while managing risks [2] Recommended Stocks - Stocks recommended based on their relative price strength include Ooma, Inc. (OOMA), ANI Pharmaceuticals, Inc. (ANIP), Matson, Inc. (MATX), Virtu Financial, Inc. (VIRT), and EverQuote, Inc. (EVER) [3] Screening Parameters - The screening criteria for selecting stocks include: - Relative price change over 12 weeks, 4 weeks, and 1 week being greater than 0 [8] - Positive current-quarter estimate revisions over the last four weeks [8] - Zacks Rank equal to 1, indicating strong buy potential [9] - Current price of at least $5 and average 20-day volume of at least 50,000 [10] Company Performance Highlights - **Ooma, Inc. (OOMA)**: Expected earnings growth of 13.6% for fiscal 2026, with a trailing four-quarter earnings surprise of approximately 18% and a share price increase of 59.3% over the past year [10][11] - **ANI Pharmaceuticals, Inc. (ANIP)**: Projected earnings growth of 21.4% for 2025, with a trailing four-quarter earnings surprise of about 17.3%, although shares have declined by 4.4% in the past year [11][12] - **Matson, Inc. (MATX)**: Current market capitalization of $4.3 billion, with a 20.6% upward revision in earnings estimates for 2025 and a share price increase of 23.7% over the past year [12][13] - **Virtu Financial, Inc. (VIRT)**: Expected earnings growth of 3.9% for 2025, with a trailing four-quarter earnings surprise of roughly 25.1% and a share price increase of 84.8% over the past year [14][15] - **EverQuote, Inc. (EVER)**: Anticipated earnings growth of 34.1% for 2025, with a significant 47.5% increase in earnings estimates over the past 60 days and a share price increase of 36.4% over the past year [15][16]

Financial Projections - Total company net revenues for 2024 are expected to be between $739 million and $759 million, reflecting a compound annual growth rate (CAGR) of approximately 33% from 2022 to 2025[10]. - Adjusted non-GAAP EBITDA for 2024 is projected to be between $182 million and $192 million, indicating a CAGR of around 50% from 2022 to 2025[14]. - Projected revenues for 2024 are estimated to be between $594 million and $602 million, representing a year-over-year growth of 22-24%[57]. - Adjusted non-GAAP EBITDA for the three months ended September 30, 2024, was $35.1 million, a decrease from $133.8 million for the same period in 2023[60]. - Adjusted non-GAAP EBITDA for the nine months ended September 30, 2024, was $106 million, down from $134 million for the same period in 2023[60]. - Adjusted non-GAAP net income available to common shareholders for the three months ended September 30, 2024, was $26.5 million[61]. Rare Disease Segment - Cortrophin Gel, the lead rare disease asset, achieved nearly $200 million in sales during its third year post-launch[10]. - Rare disease net revenues are projected to grow by 133% from 2022 to 2024, reaching between $228 million and $229 million[18]. - The ACTH market is estimated to be worth $600 million at launch in 2022 and approximately $670 million in 2024, driven by Cortrophin Gel's introduction[23]. - The company expects continued strong growth in the rare disease segment, supported by high barriers to entry and limited competition[22]. - Preliminary results for Q4 2024 indicate a 107% year-over-year increase in revenues from the rare disease segment[12]. - Cortrophin Gel achieved approximately $198 million in revenue for 2024, indicating a strong multi-year growth trajectory[56]. - Cortrophin's use for acute gouty arthritis flares has grown to approximately 15% of its total usage, with a significant addressable patient population of around 300,000[31]. - The company expects its Rare Disease business to account for over 50% of total revenues by 2025, driving future growth[54]. Product Launches and Acquisitions - The acquisition of Alimera expanded the rare disease franchise, contributing to the growth of the portfolio[10]. - The acquisition of Alimera Sciences is projected to contribute $10 million in synergies by 2025, enhancing the company's ophthalmology portfolio[33]. - A total of 17 new generic products were launched in 2024, maintaining a 2 ranking in Competitive Generic Therapy (CGT) approvals[10]. - ANI Pharmaceuticals has launched seventeen new products in 2024, including two Competitive Generic Therapy products with 180-day exclusivity[52]. - The company plans to launch a Pre-Filled Syringe for Cortrophin Gel in the first half of 2025, enhancing patient convenience[56]. - The expanded ophthalmology sales team has increased new patient starts in this area by approximately 2x quarter-over-quarter in Q4[27]. Financial Health and Expenses - ANI Pharmaceuticals has maintained a disciplined approach towards debt levels, with a post-acquisition net leverage of 3.0x[57]. - Net loss for the three months ended September 30, 2024, was $(24.2) million, compared to a net income of $18.8 million for the same period in 2023[60]. - Cash and cash equivalents increased significantly from $48 million in 2022 to $221 million in 2023[63]. - Net debt decreased from $249 million in 2022 to $73 million in 2023, resulting in a net debt/EBITDA ratio of 0.5x[63]. - The gross debt remained relatively stable at $294 million in 2023 compared to $297 million in 2022[63]. - The company incurred $9.9 million in M&A transaction expenses during the three months ended September 30, 2024[61]. - Stock-based compensation for the three months ended September 30, 2024, amounted to $7.5 million[61]. - Depreciation and amortization expenses for the three months ended September 30, 2024, were $15.7 million[61].

Core Viewpoint - ANI Pharmaceuticals (ANIP) shows potential for significant upside, with a mean price target of $80.83 indicating a 32.4% increase from the current price of $61.05 [1] Price Targets - The average price target consists of six estimates ranging from a low of $62 to a high of $94, with a standard deviation of $10.52, suggesting variability in analyst opinions [2] - The lowest estimate indicates a modest increase of 1.6%, while the highest suggests a potential upside of 54% [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement direction [7] Analyst Sentiment - Analysts have recently shown increased optimism about ANIP's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [9] - Over the last 30 days, three estimates have been revised upward, leading to a 22.5% increase in the Zacks Consensus Estimate [10] Zacks Rank - ANIP holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not be reliable for predicting exact price movements, they can provide a useful guide for understanding potential price direction [12]

Core Viewpoint - The article emphasizes the importance of identifying growth stocks with strong financial growth potential, highlighting ANI Pharmaceuticals (ANIP) as a recommended stock due to its favorable growth metrics and Zacks Rank. Group 1: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being highly desirable [4] - ANI's projected EPS growth for this year is 21.3%, significantly surpassing the industry average of 13% [5] Group 2: Cash Flow Growth - Higher-than-average cash flow growth is essential for growth-oriented companies, enabling them to expand without relying on external funding [6] - ANI's year-over-year cash flow growth is 22.1%, compared to the industry average of -0.8% [6] - The historical annualized cash flow growth rate for ANI over the past 3-5 years is 8.3%, while the industry average is 3.8% [7] Group 3: Earnings Estimate Revisions - Positive trends in earnings estimate revisions are correlated with stock price movements [8] - The Zacks Consensus Estimate for ANI's current-year earnings has increased by 22.5% over the past month [8] Group 4: Overall Positioning - ANI has achieved a Zacks Rank 1 (Strong Buy) due to favorable earnings estimate revisions and a Growth Score of B [10] - This combination positions ANI well for potential outperformance, making it an attractive option for growth investors [10]